pharma · Diabetic Peripheral Neuropathic Pain
Jemincare
Jemincare is a pharma organization headquartered in CN. Primary therapeutic focus areas include Diabetic Peripheral Neuropathic Pain. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s)
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
JMKX000623
Phase 2 · small molecule · Diabetic Peripheral Neuropathic Pain
JMKX000623 for Diabetic Peripheral Neuropathic Pain is a Phase 2 program (small_molecule) at Jemincare with 1 ClinicalTrials.gov record(s).
Internal code JMKX0623-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jemincare
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Diabetic Peripheral Neuropathic Pain
- Status
- active
- Trials
- 1